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introduction
The availability of complete genomic sequences and theemerging technologies of proteomics inspire confidencethat complex biological phenomena and systems can beunderstood completely. Such optimism is strengthenedby rapidly expanding capabilities to undertake global
analyses of biological systems, including the capacity to manipulate
gene content and expression in mammalian cells and organisms, to
detect protein–protein interactions, and to quantify the activities of
macromolecules in vivo. Such understanding of complete systems
implies (and demands) the capacity to predict quantitatively the
altered behaviour of these systems that results from their genetic or
environmental (including pharmacological) perturbation. We can
foresee, rather than simply imagine, the construction of a virtual
cell, and this accomplishment will eventually have an enormous
impact on biomedical and pharmaceutical science.
We have launched a major new research initiative called the Alliance
for Cellular Signaling (AfCS; www.signaling-gateway.org): a multi-
disciplinary, multi-institutional consortium to study cellular signalling
systems. The overall goal of the AfCS is to understand as completely as
possible the relationships between sets of inputs and outputs that vary
both temporally and spatially. The same goal, stated from a slightly dif-
ferent perspective, is to understand fully how cells interpret signals in a
context-dependent manner. How does a cell respond appropriately to
one voice when it must listen simultaneously to many, and how does it
alter this response in the context of other concurrent or recent signalling
events? Answers to these questions will require identification of all the
molecules that comprise the various signalling systems, assessment of
time-dependent information flow through the systems in both normal
and pathological states, and reduction of the mass of detailed data into a
set of interacting models that describe cellular signalling.
The organization of the alliance was catalysed by an announce-
ment by the National Institute of General Medical Sciences (NIGMS)
of plans to fund large-scale collaborative projects to “enable the solu-
tion of major problems in biomedical research and to facilitate the
next evolutionary stage of integrative biomedical science.” NIGMS
calls these ‘glue’ grants. The strategy of the AfCS includes a ten-year
research plan with an annual budget of about US$10,000,000. We
have obtained the necessary funding from NIGMS, the National
Institute of Allergy and Infectious Diseases, the National Cancer
Institute, a consortium of pharmaceutical companies (Eli Lilly, 
Aventis, Johnson and Johnson, Novartis and (briefly) Chiron) and
private donors (The Merck Genome Research Institute, the Agouron
Institute and an anonymous philanthropist). 
We plan to use these funds to answer overarching questions that
cannot be approached by individual laboratories (Table 1). We are
keenly aware of the fact that by acting alone, the alliance can acquire
only a small fraction of the necessary information.  A critical part of
our strategy is thus to catalyse complementary research throughout
the signalling community.  We provide leads for pursuit by individual
laboratories by disseminating all of our data publicly and promptly
via the Internet. Information is released as soon as it has been 
verified, and neither AfCS investigators nor our sponsors have access
to data before it is available to the public. We do experiments, but,
importantly, we are ourselves an experiment in how collaborative 
science might be accomplished.
Organization of the AfCS
The so-called participating investigators of the AfCS comprise a group
of around 50 scientists at about 20 different institutions, predomi-
nantly in the United States, with a few representatives from Canada
and the United Kingdom. Participation is enhanced by communica-
tion and data sharing by videoconference using Internet2. (Internet2
is a university-led consortium whose goal is to create a leading-edge
network capability for the national research community.)  
The participating investigators are members of various commit-
tees or are directors of AfCS laboratories (Fig. 1; and see list of 
investigators at the end of this paper). A critical interaction is that
between the laboratory directors and two ‘system committees’, 
representing the B lymphocyte and the cardiac myocyte (the two cells
of primary interest to the AfCS). The system committees are charged
with experimental planning and data interpretation, while the 
laboratory directors design and implement the experimental plan.  
There is complete separation between the AfCS laboratories and
the individual laboratories of the participating investigators. 
Participating investigators do not receive funding for their own labo-
ratories, with the exception of modest funds that are provided for a
few so-called ‘bridging projects’ (aimed at technology development).
The eight AfCS laboratories are staffed by dedicated PhD scientists
and technicians. The relatively small number of AfCS laboratories in
which work is done minimizes experimental sources of variance as
data are collected systematically. 
Membership in the AfCS constitutes another level of participa-
tion in the venture. The role of the more than 1,500 members is
described below.
Selecting the cells to be studied
We are committed to the tenet that much data must be gathered under
standardized conditions on a small number of systems to permit the
desired depth of quantitative understanding of signalling system behav-
iour. We have limited ourselves to two cell types — the B lymphocyte
and the cardiac myocyte. The two cell types were not easy choices,
indeed both pose enormous challenges, and agreement was reached
only after a great deal of discussion.  The primary criteria for choice of
cells were that they should be mammalian with a sequenced genome, a
criterion that drove us to the mouse; they should be nonmalignant and
euploid, which led us to select cells that were as normal as possible and
whose signalling systems had not been co-opted by malignant transfor-
mations; and they should be of requisite mass and homogeneity, offer
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The Alliance for Cellular Signaling is a large-scale collaboration designed to answer global questions about signalling
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myocytes —  to facilitate quantitative modelling. One goal is to catalyse complementary research in individual laboratories;
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nature and breadth of the response, including  second messenger con-
centrations, alterations in protein phosphorylation, patterns of gene
expression and, in time, concentrations of many cellular lipids. We
anticipate compilation of a list of 20 or more active ligands for each cell
type.  The single ligand screen will tell us if any one ligand is truly the
same as another (for example, how much do the agonists that work on
the distinct Gi-coupled chemokine receptors of B cells differ from each
other) and will reveal responses to be targeted for careful quantification
when we return to measure information flow through the entire system.
Measurements of responses to combinations of ligands will reveal
interactions between pathways. Interaction is revealed by energetic
(logarithmic) non-additivity. We will thus evaluate the additivity of
the log fraction (or multiple) of the output. The combinations of
inputs that yield the most extensive deviations from energetic addi-
tivity will be carried forward for rigorous analysis. We cannot fully
sample the multidimensional space of two-way ligand combinations
(various concentrations, time points, order of additions, and so on),
to say nothing of higher-order combinations.  Additionally, we have
no idea of the density of interactions that we might uncover, but some
estimate of this parameter will provide the first at least semi-system-
atic estimate of the level of complexity of cellular signalling systems.
Perturbational analysis
With parts lists and ligands in hand, we will undertake a perturba-
tional strategy to construct an epistasis map. Such approaches are as
old as pharmacology and genetics, where they were born. Most inves-
tigators would likely agree that pharmacological manipulation of a
system (be it called chemical genetics or not) has more to offer (in
terms of speed and reversibility) when cell-permeant chemicals of
high specificity are available. But the number of adequate chemical
perturbants is unfortunately small, and we must rely heavily on
nucleic acid-based techniques to manipulate gene expression to
achieve either loss or gain of function. RNA interference is particular-
ly promising, and successful application of this technology would
greatly improve the quality of our effort. Antisense approaches are
also being pursued. Just as we will apply combinations of ligands to
our experimental cells, it will become equally important to use 
combinations of perturbants.
Quantitative determination of information flow
The final experimental phase of the analysis will be the quantitative
determination of functional interactions among the signalling 
molecules. This ambitious undertaking will start when the system
committees decide that the identification of new signalling 
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the potential to manipulate gene expression, and possess interesting
biological properties regulated by interacting signalling systems.
The significant advantages and the disadvantages of these cells are
described in the accompanying articles (pages 708–710 and
712–714). There is no single cell type that satisfies all of our desires —
it is difficult to find all wanted attributes and bring all necessary tech-
nologies to a single system — and it remains to be seen if we have
struck a set of manageable compromises.
Experimental strategy
Our goal is to understand the cellular signalling networks that convert a
set of time-varying inputs into physiologically relevant outputs.  This
requires identification and localization of all the relevant molecules,
definition of the physical interactions between these molecules, and
quantitative assessment of the physiological significance of these 
interactions as information flows through the system.  Furthermore, it
is critical that this flow of information be evaluated under conditions
where interactions between combinations of inputs can be assessed, as
this is the only way to probe the level of complexity of the system.  These
conceptual requirements dictate three broad and temporally ordered
(but overlapping) experimental approaches, outlined in Table 2.
The parts list
What signalling proteins are expressed in the cells of interest, where
are they located within these cells, and do they move within these cells
in response to the flow of regulatory information? To answer these
questions we must conduct broad screens to detect interactions
between proteins and to identify players that do not yet appear on the
AfCS protein list. We are conducting yeast two-hybrid screens using
AfCS proteins as bait in collaboration with Myriad Genetics. Results
are posted on the alliance website as they are received and should 
represent a valuable source of leads for pursuit by individuals in the
signalling research community. We hope to launch other protein-
and DNA-based screens for relevant interactions in the near future.
Ligand screens 
We need to know what ligands will activate signalling pathways in the
chosen cells, what combinations of ligands will reveal interactions
between signalling pathways, and what downstream responses are 
reliable indicators of signalling activity. The single and multiple ligand
screens are designed to provide this information. B cells and cardiac
myocytes are being exposed to a large number of ligands chosen accord-
ing to information from the literature.  We are sampling cellular
responses to each ligand with a collection of assays that should reveal the
Table 1 Central questions of the AfCS
Question Experiment New technologies required
1. How complex is signal processing in cells? Considering the set of ligands for Systematic single- and double-ligand  Analytic methods to classify and  
cell-surface receptors as a potential combinatorial code of inputs, how much of this input screens to classify output responses  compare multi-dimensional data for 
complexity can a cell uniquely decode at its outputs? In other words, how big is the and determine degree of functional different ligand combinations.
AfCS problem, and can we experimentally bound the complexity of cellular signalling? crosstalk between transduction pathways.
2. What is the structure of the whole signalling network? Is the connectivity Wholesale mapping of physiologically  High-throughput assays for inter- 
sparse or dense? relevant protein–protein and small- molecular interaction in vivo, especially  
molecule–protein interactions. in response to ligand stimulation.
3. How much does network topology constrain signal processing capability? Perturbation methods (gain-of-function Methods for reliably perturbing the 
How much of function is specified by the nature of connections rather than by the and loss-of-function) coupled with high- concentration (or specific activity) of  
specific biochemical constants of individual activities? Can a functional module be throughput functional assays to test the  signalling proteins in vivo, both singly 
defined and recognized simply by network topology? role of potential network modules. and in combinations.
4. Can functional modules be abstracted mathematically? Can we make physical Mathematical modelling of network  New mathematical methods to model  
models of the network modules that explain and predict the input–output relations of modules coupled with experimental the behaviour of signalling systems. 
signalling subsystems? Can we identify the basic computations being done by these testing. Approaches to improve the interface  
modules? What is the ‘device physics’ of biological signalling components? between theorists and experimentalists.
5. What are the dynamics of the signalling network? Can we visualize how Follow the kinetics of signalling through Methods for monitoring protein activities 
perturbations to the signalling network (such as ligand application) propagate through a set of nodes in the signalling network with high temporal and spatial resolution 
the network as changes in functional activities? This represents the flow and that comprise a representative sampling in cells.
transformation of information during signalling events. of the sites of information processing.
6. Why is the network the way it is? What general thermodynamic principle operates Unknown for now. Unknown for now.
on evolved systems to make the observed solutions to information processing the
chosen ones? What is being optimized so that the signalling network looks and 
behaves the way it does?
© 2002 Nature Publishing Group
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molecules and their interactions is approaching saturation. The data
from this effort will allow us to attain our goal of  performing the first
molecular analysis of how a signalling network actually works.
For this goal, it will almost certainly be inappropriate to adopt the
traditional reductionist approach of simply measuring in vitro all the
Kd, Km and Vmax values, cooperativity constants, rate constants and
molar concentrations for all molecules involved. One reason is that it
is unlikely that any artificial solution (medium) will allow approxi-
mation of the physiological magnitude of these values. Multiple 
specific interactions of a single molecule in the cell will also be 
impossible to duplicate in vitro. And determination of the vast array
of values that the strict reductionist approach demands will probably
be technologically impossible in the foreseeable future, and their
manipulation to yield a model of cell function would be daunting.
An alternative approach to quantifying the matrix of regulatory
interactions in the cell is to measure functional interactions on essen-
tially arbitrary scales for each molecule that we test, and then to link
fractional output (fractional activation, activity and binding) of one
molecule with its fractional effect on those with which it interacts. In
general, we will stimulate and/or inhibit the activity of each molecule
p over a defined range and measure consequent changes in the activi-
ties (or other parameters) of all molecules qn with which p interacts
directly in a functionally important way. By asking how much of the
maximal activity of p does it take to produce fractional activation of
q1, q2, ..., qn, we hope to arrive at a set of linkage functions that should
in principle be determined by fractional activation of receptors by
ligands and be interpretable as fractional physiological outputs.
What are the experimental parameters that will give us these frac-
tional activities? Each will depend on the type of molecule measured.
For Ca2+, concentration is adequate, and appropriate assays are
already available. For a protein phosphatase, activity will vary with
substrates, and fractional activation towards one substrate will not
necessarily equal that towards another, as modulation can change
specificity. Conceptually, any ‘reporter’ will do, but reporters must be
closely linked to the molecules whose activities they describe or their
information will be degraded (filtered) by other interactions in the
signalling network. Development of appropriate in situ signalling
assays is one of the more rapidly evolving technologies, and the
alliance will draw on the leaders in this field. Spectroscopic outputs
are clearly preferable, and product traps for enzymes that synthesize
stable, low-molecular-weight molecules are also desirable.
Data modelling and network analysis
The alliance is built on two independent developments that have
become prominent during the past decade: the success of molecular
biology in developing tools to identify the component parts of 
biological systems and their interactions, and the development of
mathematical and computational tools for the analysis and design 
of complex engineering systems. 
The first of these advances provides measurement technology to
yield quantitative assessments of the state of components of biologi-
cal networks (for example, transcripts, small ions, labelled proteins
and cell shapes) that begin to equal the tools used for the analysis of
other engineering networks. In fact, the early stages of the alliance’s
efforts are devoted to the further identification of the components 
of cellular signalling networks and the quantitative measurement of
their input–output behaviours and regulation. But appreciation 
of the  biological implications of these measurements will be largely
impenetrable without data analysis and modelling tools designed
specifically for biological network systems. Thus the final stages 
of the alliance’s activity must address the ‘complex systems’ aspects of
biology, building on methods from systems engineering, computer
science, control theory, circuit design and dynamical systems. 
The current charge of the alliance’s network analysis team is to
produce the necessary theoretical and computational framework 
to achieve these final goals. This requires close interactions with the
database and informatics teams to create data structures and tables
appropriate for network analysis, and with the system committees to
assure that the experimental procedures yield data that are appropri-
ate for network prediction and analysis. We must create tools for
organization and analysis of these data and then build static and
dynamic models of system function that can be validated experimen-
tally. These models can then be used to design practical biomedical
strategies for control of these pathways and their associated disease
states. Thus, this team must forge the necessary tight cycle of experi-
ment, theory and computation that is the hallmark of the analysis
and engineering of networks in other fields of inquiry, and the
alliance has been structured to permit this type of interaction.
Establishment of a signalling database
The AfCS will sponsor and coordinate the establishment of a signalling
database that will be an invaluable resource for the entire signalling
Table 2 An overview of the experimental strategy of the AfCS
Identify and localize the relevant molecules Define and expand the molecule list Define the flow of information
1. Define basic scope, including pathways of 1. Broad screens to detect interactions between proteins. 1. Choose the inputs using broad assays to eliminate  
interest and an initial list of molecules. (I)* The goal is to define and expand the list of molecular redundancy and detect interactions. (I) 
2. What molecules are present? Large-scale players, and to identify ‘all’ of the interactions among the 2. Define intermediate endpoints. (I,L) 
transcriptional profiling. (I) components. The research community at large will define 3. Choose the outputs. (I,L) 
3. Quantify proteins of interest (using the physical and physiological validity of these interactions. 4. Measure intermediate endpoints and outputs as a 
immunoblotting, ligand binding). (I) The alliance will define the further physiological validity and function of inputs (for example, time, concentration,  
4. Localize proteins of interest (by microscopy, the quantitative physiological significance of these combinations) while altering functional concentrations of  
subcellular fractionation). (I) interactions in its two cellular systems. (I) components (the molecule list, singly and in combinations)  
5. Monitor movements of proteins, preferably pharmacologically and ‘genetically’. (L) 
quantitatively and in real time (for example,  5. Define quantitative relationships between activity states 
using GFP fusions); also a quantitative  of interacting components; assays in real time in vivo
intermediate endpoint. (I) and snap shots of intracellular activity. (L) 
6. Develop and test models. (L)



























Figure 1 AfCS organizational chart.
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further studies in individual laboratories. The alliance offers this
opportunity in a unique way, but only to those who are willing to
donate a part of themselves to the group. We need socialistic science
practised by strong individualists. Practical? We believe it is. ■
doi:10.1038/nature01304
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research community. The central element of this database will be the
‘Molecule Pages’, which will aim to represent every protein on the AfCS
list (see article on pages 716–717). These will be standardized 
documents that each contain a wealth of literature-derived information
about a given molecule; additional information from the alliance labo-
ratories will be incorporated in time. Linkages will be provided between
Molecule Pages to maps of signalling pathways as they are developed
and refined, to the original literature, and to other databases. 
Molecule Pages will be prepared (and updated) by AfCS members
and will be peer reviewed, the entire process being supervised by an
editorial board and Nature. We believe strongly that the collection
and interpretation of the considerable amount of information about
a given protein and its entry into a complex object-relational 
database is a substantial scholarly effort — at least as important as a
conventional written review because of the powerful nature of the
database itself. Given peer review of these Molecule Pages and the
important collaboration between the AfCS and Nature Publishing
Group, we believe that AfCS Molecule Pages should and will have the
cachet of a major publication in Nature or a similar high-profile 
journal. Members will be chosen particularly for their expertise
about specific molecules and pathways, and applications for 
membership have been and will continue to be encouraged publicly
via our website.
Socialistic aspects of the AfCS concept
The alliance is itself an experiment in collaborative science. There
have been relatively few large-scale collaborations in basic biology. It
is a young science that has flourished to date in the hands of 
individual investigators, directing relatively small laboratories. But
the scientific questions posed by the AfCS are not suited to the 
traditional distributed approach to experimental biology.
Are there impediments to large-scale collaboration? There are 
significant nuisances, but they pale by comparison with the potential
gain. Obvious difficulties imposed by distance can be largely circum-
vented with modern communication systems; the AfCS does not
function without the Internet.  Human and career issues are signifi-
cant —scientists are no less egocentric or competitive than others.
We may be endowed with exuberant senses of curiosity, but we can lay
no collective claim to sainthood. In addition, the academic reward
system compounds the problem, and the AfCS does not provide a
wealth of conventional academic rewards.
It is essential that we distribute data publicly and promptly via the
Internet; publications of experimental observations (but not 
analyses) are thus largely superfluous. The vast majority of AfCS
funding is spent in the AfCS laboratories to optimize precision and
standardization of data collection. The classical promotion and
tenure system needs adjusting to recognize an individual’s contribu-
tions to group efforts if large-scale biology is to come of age. 
Physicists have learned the art of large-scale collaboration because of
collective needs for extremely expensive facilities. Biologists will
learn the same art because of the overwhelming complexity of the
problems to be solved.
Our challenge is substantial, and it can be met only by the coordi-
nated and cooperative efforts of many, in roles ranging from prepara-
tion of Molecule Pages by our members, to donation of significant
amounts of time and energy by our participating investigators, to
full-time employment by AfCS laboratory scientists and technicians.
These contributions will benefit the entire field enormously and
expand the opportunities for everyone. Those involved with this 
project see the need clearly and bring their own motivation to the
project. We are excited by the idea that key questions about cellular
information processing can be answered by a collective approach and
that such understanding will produce new paradigms to guide 
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